FactaeThe Factual News

Top Stories Focus Media

🌍Monde
France
🏛️Politique
🪖Guerre
🚨Défense & Sécurité

💰Économie
📈Marchés
⚡Énergie
💹Crypto

📱Tech
🤖Intelligence artificielle
💻Informatique
🛡️Cybersécurité

🔬Science
🏥Santé
🌿Écologie

📖Histoire
🏅Sport
🖼️Culture
⚖️Droit
🎓Éducation

Factae

The Factual News

The intelligence of the news. Multi-source, geolocated, synthesized.

Live

Live feed Scoops Immersive map

Explore

Trading Board Trends AI models AI for developers Sources

Information

About Methodology RSS feed Contact Terms Privacy Legal Newsletter

© 2026 Factae. All rights reserved.

Home/📈 marches

📈

Genfit selected among Portzamparc's 8 top picks for 2026

French biotech Genfit is listed among Portzamparc's 8 top picks.

Published 1j·1 sourceNotable·updated 20h

Lire en français

≈ 16sSpeed

The fact

The broker bets on its potential in biotech for the second half of the year.

CEO Pascal Prigent highlights promising prospects.

🔗Click the link to read an article on the topic:

📈

🧭Explore this topic

📍Paris 📍France 👤Pascal Prigent 🏢Genfit 🏢Portzamparc #Genfit #biotechnologies #Bourse de Paris #Portzamparc #investissement

What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.→

ParisWorld map →

Follow topic →

Auto-synthesis from 1 media source · identified on July 15, 2026

← Back to home

Discover

Read more

All marches →

Genfit: French biotech status on April 12, 2026

13sem · 1 source 📈marches

Genfit faces takeover bid as key investment opportunities emerge

5sem · 1 source 📈marches

Biotech and small-cap stocks targeted by analysts

10sem · 1 source 📈marches400 million dollars

Genfit targets 400 million dollars revenue in 2026

11sem · 1 source 🏥sante

Biotech stocks show mixed moves in Paris

11sem · 1 source 📈marches

Genfit: sharp royalty surge and potential diagnostic expansion

13sem · 1 source